ATS 2024 Final Program

Click on the session title to view the speakers

233

TUESDAY • MAY 21

812 Type 2 Inflammation Is Associated With CT Emphysema 813 Predicting Endobronchial Valve Treatment Response in Emphysema Patients Using Quantitative Measures Extracted From Chest CT Scans 814 Computer Assisted Quantitative Image Analysis as a Pathway to Identification of Combined Pulmonary Fibrosis and Emphysema (CPFE): Analysis of the SPIROMICS Cohort 815 CT-derived Functional Imaging Biomarkers to Predict 10-year All-cause Mortality in COPDGene Cohort 816 Cardiovascular Biomarkers and Their Relationship to Radiologically Detected Coronary Artery Disease in Stable COPD and During Community-treated Exacerbation Classification Using Sex-specific Machine Learning Models and Quantitative Computed Tomography Imaging 818 Airway Mucus Plugging and Cause-specific Mortality in COPD 819 PODE: A Prognostic Score Using Quantitative Measurement of the Pectoralis Muscle and Subcutaneous Fat Area in Chronic Obstructive Pulmonary Disease 820 Bronchoscopic Lung Volume Reduction Is Associated With Increased Pectoralis Muscle Mass Post-procedure in Chronic Obstructive Pulmonary Disease Patients 821 Activin A Is an Associating Factors With Preserved Ratio Impaired Spirometry and Cognitive Function Impairment 822 The Protease Anti-protease Balance in Chronic Obstructive Pulmonary Disease and Alpha-1 Antitrypsin Deficiency 823 Clinical Characteristics and Health Care Resource Utilization Among Individuals Undergoing Alpha-1 Antitrypsin Testing in a Quaternary Health System 824 Screening for Type 2 Inflammation and High Exacerbation Endophenotype in COPD 817 Chronic Obstructive Pulmonary Disease

BASIC • CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION

C24 CLINICAL, BIOLOGIC, AND

RADIOLOGIC MARKERS OF KEY OUTCOMES AND TREATMENT RESPONSE IN COPD

9:15 a.m. - 11:15 a.m.

San Diego Convention Center Room 31A-C (Upper Level)

Poster Viewing

9:15-10:00

Discussion 10:00-11:15 801 Psychobiologic Correlates of Stress: An Analysis of Perceived Stress, Nail Cortisol, and Serum Cortisol in Individuals With COPD 802 Platelet Activation and Oxidative Stress as Potential Biologic Mechanisms of Psychological Stress in COPD 803 Platelet Activation Is Associated With Respiratory Exacerbation Rate and Symptoms in SPIROMICS 804 Protein Biomarkers Predictive of Acute Exacerbations in SPIROMICS and COPDGene 805 Differential Cytokine Profiles in Stable COPD Vs Acute Exacerbations 806 Impact of Secondary Polycythemia on In-hospital Outcomes in Patients Admitted for Acute Exacerbation of Chronic Obstructive Pulmonary Disease 807 Use of the Biofire Assay for Acute Respiratory Infection (ARI) Testing in the Community to Guide Antimicrobial Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Asthma Exacerbations 808 Nasal Mucosal Immune Biomarkers and Microbiome Among COPD Exacerbation Phenotypes: An Observational Study 809 Insights into Immunogenetic Variability in the IgG Heavy Chain in COPD 810 Eosinophilic Heterogeneity in COPD: How Stable Is the Eosinophilic Phenotype? 811 Clinical Correlates of Exhaled Nitric Oxide in Patients With Eosinophilic COPD

ATS 2024 Conference Program • San Diego, CA